)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dermapharm
Dermapharm (DMP) investor relations material
Dermapharm Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Q3 revenue was €293.4m, down 0.5% YoY; adjusted EBITDA fell 3.6% to €84.9m, with lower BioNTech contribution and higher depreciation weighing on results.
9M revenue rose 1.7% to €884.4m and adjusted EBITDA increased 5.1% to €248.1m, led by Branded Pharmaceuticals.
9M operating cash flow grew 10.2% to €148.6m; earnings after tax was €93.3m versus €95.2m a year earlier.
FY 2026 guidance was reaffirmed at revenue of €1,182m–€1,218m and adjusted EBITDA of €331m–€341m.
Financial highlights
9M operating result rose to €193.3m from €169.1m; EBT was €131.3m versus €137.4m and profit for the period was €93.3m versus €95.2m.
9M unadjusted EBITDA increased 15.6% to €266.9m; adjusted EBITDA margin rose to 28.0% from 27.1%.
9M free cash flow increased €16.6m to €113.1m; cash conversion improved to 59.9% of adjusted EBITDA from 57.1%.
Q3 Branded Pharmaceuticals revenue grew 1.7%; management reported no exceptional quarterly factor and said it would review revenue phasing.
Outlook and guidance
FY 2026 revenue guidance of €1,182m–€1,218m and adjusted EBITDA guidance of €331m–€341m were reaffirmed, supported by Q4 expectations.
Branded growth is expected from the existing portfolio, expansion, seasonal anti-allergy demand and international business; no material 2026 impact from the German Financial Stabilisation Act is anticipated.
Other Healthcare Products revenue and Parallel Import contribution margin are expected slightly below prior year, offset particularly by Branded Pharmaceuticals; leverage is forecast below 3x adjusted EBITDA by year-end.
Arkopharma expects further acceleration in 2027, supported by customer feedback, pre-orders, media campaigns and new product launches.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dermapharm
- Revenue and profit rose in H1 2026, with strong branded pharma growth and confirmed outlook.DMP
Q2 2026 - Revenue and profit rose, led by branded pharmaceuticals and margin gains.DMPQ1 2026
- Adjusted EBITDA rose 2.9% to EUR 324.8m despite a 1.3% revenue dip in 2025.DMPQ4 2025
- Branded pharma growth and margin gains offset declines; full-year guidance remains on track.DMPQ3 2025
- Branded pharma growth offsets revenue and EBITDA decline; full-year outlook confirmed.DMPQ2 2025
- Revenue and earnings rose, with guidance for 2024 confirmed.DMPQ3 2024
- Branded pharmaceuticals growth offset segment declines as profit and guidance rose.DMPQ2 2024
- Revenue rose but profit and margins fell as costs and restructuring weighed on Q1 2025.DMPQ1 2025
- Dermapharm exceeded 2024 EBITDA targets and grew net income 84.6% year-over-year.DMPQ4 2024
Next Dermapharm earnings date
Q4 202625 Mar, 2027
Dermapharm
Next Dermapharm earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dermapharm Holding SE is a Germany-based pharmaceutical company specializing in the development, production, and marketing of branded prescription and over-the-counter (OTC) medicines, dietary supplements, and medical devices. The company focuses on niche markets, offering a diverse portfolio of products across therapeutic areas such as dermatology, allergy, and pain management. Dermapharm also provides contract manufacturing services to third-party pharmaceutical companies. The company is headquartered in Grünwald, Germany, and its shares are listed on the Frankfurt Stock Exchange.